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Introduction: EGFR-TIKs showed about twenty percent of response 
rate in refractory non-small cell lung cancer. Clinical trials of cytotoxic 
drugs and EGFR-TIKs failed to show improved survival compared 
to platinum based doublets. An antagonism between EGFR-TKIs and 
cytotoxic chemotherapy drugs was raised as a possible explanation for 
the negative results. 
Materials and Methods: The antiproliferative effects and cell cycle 
distributions after treatments with EGFR-TKIs(geﬁtinib and erlotinib) 
and cytotoxic drugs(Docetaxel, Paclitaxel, Gemcitabine) were studied 
using a cell line(NCI-H1975, adenocarcinoma of lung) harboring 
T790M mutation in exon 20 of EGFR gene. The cell viability assay and 
cell cycle analysis were performed with MTT assay and ﬂow cytome-
try. EGFR-TKIs and cytotoxic drugs were treated in different sequenc-
es to observe sequence dependent effect. Calcusyn software(Biosoft, 
Cambridge, UK) was used to calculate combination index(CI). 
Results: Various combinations of cytotoxic drugs and EGFR-TKIs 
showed different antiproliferative effects on NCI-H1975 cell line. 
Antagonisms(CI>1) were observed when EGFR-TKIs were treated 
before cytotoxic drugs(EC sequence), while synergisms(CI<1) were 
observed when cytotoxic drugs were pre-treated before EGFR-
TKIs(CE sequence). Treatment in EC sequence arrested the cells in 
G0/G1 phase and decreased the apoptotic fraction. However, treatment 
in CE sequence arrested the cells in G2/M phase and higher fractions of 
apoptotic cell death were observed. 
Conclusion: To combine EGFR-TKIs and cytotoxic drugs, sequence 
dependent anti-proliferative effects should be considered. 
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Galectin-9 is a member of the β-galactoside-binding galectin family 
proteins associated with diverse biological processes, such as apopto-
sis, cell aggregation and eosinophilic chemoattraction. Some reports 
described that galectin-9 was a possible prognostic factor in breast 
cancer and melanoma.
We have found stromal spindle cells are occasionally positive for ga-
lectin-9 in our previous study (data not shown). Herein, we investigated 
its clinicopathological signiﬁcance using lung cancer tissue microarray 
(TMA). We immunohistochemically examined the expression of galec-
tin-9 in lung cancer using TMA containing samples from 400 surgical 
cases. Cancerous stroma was microscopically recognized in 183 cases 
(109 adenocarcinoma, 70 squamous cell carcinoma and 4 adenosqua-
mous cell carcinoma cases). 
Total of 24.6 % cases (45/183) showed galectin-9 expression in stromal 
spindle cells. We examined the survival statistical signiﬁcance of ga-
lectin-9 using the log-rank test, and Kaplan-Meier curves were plotted. 
Positive immunohistochemical staining with galectin-9 was associated 
with favorer survival for patients with lung cancer (5-year survival of 
59.2% versus 31.3% p=0.0206).
Conclusion: Our data indicates that galectin-9 in cancerous stroma can 
be a better prognostic biomarker in lung cancer.
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Podoplanin is a mucin-type glycoprotein and a noble lymphatic endo-
thelial marker. Immunohistochemical staining against podoplanin is 
currently a useful tool to detect lymphatic involvement of cancer cells, 
and is widely used in a routine pathological diagnosis. By observation 
of daily cases, we have noticed stromal spindle cells are occasionally 
positive for podoplanin. To conﬁrm its presence and to investigate its 
clinical signiﬁcance, we immunohistochemically examined podoplanin 
expression using several monoclonal antibodies and tissue microarrays.
We found that stromal podoplanin expression in adenocarcinoma was 
signiﬁcantly associated with poorer prognosis (p<0.001). The prognos-
tic signiﬁcance was still high after adjustment with stage, gender, age, 
and histological differentiation (p<0.001). The expression was associ-
ated with differentiation and tended to associate with nodal metastasis. 
Also we immunohistochemically examined with 14 common cancer 
types and found that podoplanin expression was signiﬁcantly associated 
with nodal metastasis (p<.01). Our data indicates that podoplanin ex-
pression in cancerous stromal cells may play a critical role in lymphatic 
invasion of cancer cells to determine patients’ survival. 
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Background: Apoptosome pathway dysfunction in tumor cells may 
account for their apoptosis resistance and there is evidence that sur-
vivin (Sur) and some its alternative splice variants may be involved in 
regulation of this cell death pathway in malignant tumors. In this work, 
we studied the expression of transcripts encoding Sur and its splice 
variants Sur-3B, Sur-2B and Sur-ΔEx3 in non-small cell lung carci-
noma (NSCLC) tissues and lung parenchyma from surgically treated 
patients and examined the impact of survivin gene promoter genotype 
at nucleotide -31 and of the smoking status of NSCLC patients on the 
expression level of the indicated Sur transcript variants. 
Methods: The expression of mRNAs encoding Sur, Sur-3B, Sur-2B 
and Sur-ΔEx3 was quantitated by real time RT-PCR using transcript-
speciﬁc oligonucleotide primers and TaqMan ﬂuorogenic probes, and 
an input of total RNA isolated from NSCLC and lung tissues. The 
expression of Sur transcript variants was normalized against the expres-
sion of β-actin mRNA. Genotyping of the survivin gene promoter in 
NSCLC and lung tissues was performed by PCR ampliﬁcation and 
DNA sequencing of the puriﬁed PCR product with nested primers. 
